Targovax - Småprat 2020 (TRVX)

[Fornybar]

Hvem tar på seg jobben med å refreshe oss på tidligere data, antall pasienter vi får nå osv?

[TheObserver]

https://www.mskcc.org/cancer-care/doctors/dmitriy-zamarin?amp

[Cinvest]

Dette er det som har blitt meldt så langt mener jeg på :

Targovax announces start of the expansion part in the phase I/II trial with...

I oktober 2018(!) var 7 pasienter innrullert. Selskapet meldt om bra til veldig bra rekruttering gjennom de Q jeg var vitne til gjennom 2019. Vi er nå i “part 1”.

Studieoppsett :

Dette er ikke priset inn i f.eks Edison sin analyse, så dette kan potensielt bli en skikkelig stor oppside med det pasientgrunnlaget som er lagt til grunn. At de skal ha abstrakt/presentere på ASCO er veldig spennende.

[Fornybar]

Fra Edison i følge @solvoll
“With its Q420 results, Targovax reported that the trial, which is being run at the six top US hospitals, is progressing well. The safety and dose escalation cohorts have been completed without no concerns, and patient recruitment into the experimental part is ongoing.”

Dette forteller meg at de nå rekrutterer i fase 2-delen av studien. Stemmer det?

[Cinvest]

Dette forteller meg at de nå rekrutterer i fase 2-delen av studien. Stemmer det?

fase 1 av “expansion” vil gi go/no go til å rekruttere videre til “part 2” det er slikt studien er bygd opp. Kriteriene er listet opp i sliden jeg refererte til.

Mer eksakte tidslinjer : (dose ekskalering)
11.10.2018 bekreftet Dr. Dmitriy Zamarin at vi hadde rekruttert 7 pasienter inn i studien. “7 patients enrolled and treated to date”

Q1 19 : “The peritoneal trials recruited very well”

15 juli 19 : Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Q3 19 : “The combination trial with AstraZeneca’s checkpoint inhibitor Imfinzi in peritoneal malignancies has also progressed well”

Jeg er faktisk litt usikker på hvor mange pasienter som ble rekruttert inn i dose-eskalering og safety lead-in. Minimum 7 pasienter, ref KOL dagen i 2018. Fase 1 av expansion kohorten skal ha 18 pasienter i Ovarian, og 13 pasienter i colorectal. Der har man satt seg predefinerte mål som må innfries for å fortsette studien. Totalt 75-78 pasienter “if all goes well”.

Fra Q4 19’ rapporten
Peritoneal malignancies
The combination trial with AstraZeneca’s checkpoint inhibitor Imfinzi in peritoneal malignancies is also progressing well. This trial is run at six top US hospitals, treating patients with ovarian and colorectal cancer that has spread to the peritoneum, the inner lining of the abdomen. Patients with this condition have bad prognosis with few treatment alternatives. If ONCOS-102 can immune activate these patients, the use of CPIs can be expanded into this indication. This trial is financed and run by Cancer Research Institute (CRI) and Ludwig Cancer Research, and Targovax was selected to participate with ONCOS-102 as the virus of choice for this trial. The safety and dose escalation cohorts have now been completed without any concerns, and patient recruitment
into the experimental part is ongoing. We hope data can be presented from this trial during 2020

[Savepig]

Ser ikke dette studiet på listen hans der?

Denne linken mot amerikanske kols, Memorial Sloan Kettering og nå styrelederen er jo compelling så det koker etter i TRVX.

Targovax er priset til 60 millioner USD. Microcap, og de har et temmelig modent OV program.

Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus...

[Fornybar]

Jess, jeg er convinced. Det blir spennende å se hvor mange pasienter og hva slags data de får ut av dette. Edison mener dette er den mest sannsynlige indikasjonen hvor de kan få en kommersiell avtale leser jeg.

[solvoll]

Edison mener dette er den mest sannsynlige indikasjonen hvor de kan få en kommersiell avtale leser jeg.

Av AZ samarbeidet og Sotio samarbeidet😊

In our view, this collaboration is the most likely of the two ONCOS-102 collaborations to translate into a commercial opportunity in the near term.

[Bob_le_Plast]

Som @Savepig påpeker ang mcap: trvx er i alle sammenligninger svært lavt priset.

Ja, selskapet har mer enn doblet seg fra bunnen av covid - myra rundt 20.mars, men med den pipelinen og potensialet for å bedre responsen til cpi så synes det ikke urealistisk at dobling av mcap kan forsvares.

Men selskapet evner ikke helt å forføre OB. Ennå… Daglig omsetning er sjeldent noe å snakke om.

[Cinvest]

Litt tidslinjer rundt release av abstrakt og tidspunkt for den virtuelle konferansen.

MAY 13, 2020 AT 5:00 PM ET
The Majority of Abstracts Released on ASCO Meeting Library

https://meetinglibrary.asco.org/results/oncos-102?page=1

… Med andre ord, nærmer seg.

MAY 29-31, 2020
ASCO20 Virtual Scientific Program

• MAY 29 at 8:00 AM ET: Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, will be available on demand
• MAY 30-31: ASCO Virtual Scientific Program Broadcast Schedule
  https://meetings.asco.org/am/dates-know

[Cinvest]

If ONCOS-102 can immune activate these patients, the use of CPIs can be expanded into this indication

Som nevnt tidligere vil jeg tro AstraZeneca følger med på denne studien da dette kan åpne et stort markedet for dem. Om de ikke har gjort det inntil nå, vil jeg ihvertfall tro at gode data herifra i en så profilert studie med MSK, CRI og Ludwig i spissen virkelig vil sette oss på kartet internt der. Ettersom de har fått godkjent ASCO abstrakt vil jeg anta at dataene har noe for seg så langt.

Edit, her er hele abstrakt tittelen
“ASCO VIRTUAL SCIENTIFIC PROGRAM
Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.”

[busk1]

“ASCO VIRTUAL SCIENTIFIC PROGRAM
Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results.”

Hva mener de med “translational results” i denne sammenhengen? Noen som kjenner fagspråket godt nok til å komme med en kvalifisert gjetning?

EDIT: Min gjetning etter innspill fra andre er at “translational results” handler om hvorvidt observerbare biologiske endringer (som f.eks. typer av immunrespons) gjenspeiler det man har sett preklinisk i mus og andre modeller. Dette til forskjell fra kliniske resultater som har effekt på sykdomsforløpet, inkludert bivirkningsprofil.

[tusekakk]

Regner med at det kan ha noe med dette å gjøre:

Translational research

[Realize_1]

Melanom

http://www.sharethiscontent.net/Actions/social_share_version.cfm?message_id=18552529&user_id=SITC&recipient_id=4500737196&jobid=47821814&isRecip=1

[TekBot]

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the “Company”)
on 29 April 2020 (the “AGM”) where election of members to the board of directors
was according to the nomination committee’s proposal. At the same AGM of the
…

Vis børsmeldingen

Company the board of directors was authorized to extend the Company’s restricted
stock unit (“RSU”) program and to issue RSUs to the board members. The RSUs are
non-transferable and each RSU gives the right and obligation to acquire one
share in the Company at a price of NOK 0.10 per share (corresponding to the
nominal value of the shares) subject to satisfaction of the applicable vesting
conditions.

If the board members choose to receive the board remuneration in RSUs they must
elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3
of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the
compensation in cash and 1/3 in RSUs. The number of RSUs is calculated on the
basis of a board remuneration of NOK 500 000 to the chairperson of the board and
NOK 290,000 to the other board members, divided by the market price of the
Company’s shares calculated as the average share price for the 10 trading days
prior to the AGM being NOK 6.81 per share.

Robert Burns has resolved to receive his full board remuneration, as determined
by the Company’s annual general meeting in 2020, in the form of RSUs and the
board of directors has resolved to issue 42,604 RSUs to Robert Burns. Robert
Burns holds 88,351 RSUs, 21,235 options and 86,020 shares in the Company.

Eva-Lotta Allan has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2020, in the form of RSUs
and the board of directors has resolved to issue 14,201 RSUs to Eva-Lotta Allan.
Eva-Lotta Allan holds 29,450 RSUs, no options and 51,368 shares in the Company.

Diane Mellett has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2020, in the form of RSUs
and the board of directors has resolved to issue 14,201 RSUs to Diane Mellett.
Diane Mellett holds 35,499 RSUs, no options and 44,149 shares in the Company.

Damian Marron has resolved to receive 1/3 of the board remuneration, as
determined by the Company’s annual general meeting in 2020, in the form of RSUs
and the board of directors has resolved to issue 24,485 RSUs to Damian Marron.
Damian Marron holds 24,485 RSUs, no options and no shares in the Company.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[TekBot]

Targovax ASA appoints Dr Victor Levitsky as Chief Scientific Officer

Oslo, Norway, 30 April 2020 - Targovax ASA (OSE: TRVX) announces the appointment
of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer (CSO). He will play a
leading role in driving research strategy and pipeline expansions, particularly
…

Vis børsmeldingen

the scientific and mechanistic aspects of early clinical work. Dr Levitsky will
serve as a member of Targovax’s management team.

Dr Levitsky is a seasoned internationally recognized expert in immunology,
oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of
preclinical, translational and early stage clinical drug development. He brings
extensive experience in pre-clinical drug development of protein-based biologics
and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and
post-doctoral training in tumor biology at Karolinska Institute, Sweden. He
spent the first 20 years of his career as an academic research scientist,
including Associate Professor positions at the Karolinska Institute in Sweden
and the Johns Hopkins University School of Medicine in the US. Before joining
Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal
Scientist with Roche in Zurich, and his most recent position has been VP, Head
of Oncology Research at Molecular Partners, Zurich, Switzerland.

Dr Levitsky is the author of numerous scientific publications.

Øystein Soug, CEO, commented: “It is with great enthusiasm that we welcome Dr
Levitsky to Targovax! With his broad and deep oncology experience and with his
background as a virologist, he will bring important scientific leadership to
Targovax. As we progress towards several important data read-outs and move
forward with our pipeline expansion initiatives, Victor will play an
instrumental role in shaping the future for Targovax.”

Dr Levitsky added: “I am very excited to be joining Targovax at what is clearly
an important stage for the company. The oncolytic virus and mutant RAS
technology platforms have clear potential to benefit cancer patients through
current and multiple novel strategies, and I look forward to joining the strong
team at Targovax to help build the scientific framework for bringing these
promising products to patients.”

Dr Levitsky will commence as CSO on 4[th] May.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[InVivo]

Before joining
Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal
Scientist with Roche in Zurich, and his most recent position has been VP, Head
of Oncology Research at Molecular Partners, Zurich, Switzerland.

Liker bakgrunnen!

Chief Scientific Officer (CSO)

Dette er en ny stilling i Trvx, ja? Fryktet først at Magnus Jaderberg var ute, men han er jo CMO, Chief Medical Officer.

[Savepig]

John Hopkins er vel et av de ledende universitetene i verden på feltet?

[Fornybar]

www.researchgate.net/profile/Victor_Levitsky

[Kjebekk]

Synes dette lover svært godt.

Ville noen med en slik CV og bakgrunn hoppe ombord på targovax skuta i disse tider om ikke han hadde god tro på at dette kan bli gull fremover?